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Abstract
Background: The increasing use of silver nanoparticles (AgNPs) in consumer products is concerning. We examined
the potential toxic effects when inhaled in Brown-Norway (BN) rats with a pre-inflammatory state compared to
Sprague–Dawley (SD) rats.
Methods: We determined the effect of AgNPs generated from a spark generator (mass concentration: 600–800 μg/
mm3; mean diameter: 13–16 nm; total lung doses: 8 [Low] and 26–28 [High] μg) inhaled by the nasal route in both
rat strains. Rats were sacrificed at day 1 and day 7 after exposure and measurement of lung function.
Results: In both strains, there was an increase in neutrophils in bronchoalveolar lavage (BAL) fluid at 24 h at the
high dose, with concomitant eosinophilia in BN rats. While BAL inflammatory cells were mostly normalised by Day
7, lung inflammation scores remained increased although not the tissue eosinophil scores. Total protein levels were
elevated at both lung doses in both strains. There was an increase in BAL IL-1β, KC, IL-17, CCL2 and CCL3 levels in
both strains at Day 1, mostly at high dose. Phospholipid levels were increased at the high dose in SD rats at Day 1
and 7, while in BN rats, this was only seen at Day 1; surfactant protein D levels decreased at day 7 at the high dose
in SD rats, but was increased at Day 1 at the low dose in BN rats. There was a transient increase in central airway
resistance and in tissue elastance in BN rats at Day 1 but not in SD rats. Positive silver-staining was seen particularly
in lung tissue macrophages in a dose and time-dependent response in both strains, maximal by day 7. Lung silver
levels were relatively higher in BN rat and present at day 7 in both strains.
Conclusions: Presence of cellular inflammation and increasing silver-positive macrophages in lungs at day 7,
associated with significant levels of lung silver indicate that lung toxicity is persistent even with the absence of
airway luminal inflammation at that time-point. The higher levels and persistence of lung silver in BN rats may be
due to the pre-existing inflammatory state of the lungs.
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Background
Silver nanoparticles (AgNPs) are often suspended in a li-
quid which can be aerosolised or used in a solid form
and are widely used as anti-microbials in consumer
products especially for textiles, personal hygiene prod-
ucts, medical equipment, wound dressings, respiratory
devices, catheters and disinfectant sprays. Therefore,
humans run the risk of inhaling AgNPs [1]. What is
known about the potential pulmonary toxicity of inhaled
AgNPs has been limited to studies in rodents. Sub-
chronic inhalation of AgNPs induced mild, dose-
dependent pulmonary inflammation and alterations in
pulmonary function [2–6], with evidence that inhaled
AgNPs may also enter the systemic circulation to be-
come distributed to extra-pulmonary organs such as the
liver and brain [2, 7, 8]. Exposure of rats to AgNP aero-
sols for 90 days led to modest increased pulmonary
function changes, with evidence of genotoxicity and ac-
cumulation of tissue macrophages [9], with persistence
of lung function and inflammatory changes for up to
12 weeks after cessation of exposure [10]. On the other
hand, studies using lower inhaled doses have reported
minimal or no toxicity [7, 11–13]. By contrast, direct in-
stillation of AgNPs produced higher levels of inflamma-
tion, oxidative stress and cytotoxicity compared to
AgNP inhaled at similar doses [14–16].
In our previous study, the inflammatory response in-
duced by intratracheal instillation of AgNPs was
dependent on particle size with a greater pulmonary in-
flammatory response with a 20 nm size than an 110 nm
size but with little influence imposed by citrate or poly-
vinyl phosphate-capping [15]. We also observed a pul-
monary inflammatory response characterised by an
intense eosinophilia and neutrophilia in the Brown-
Norway (BN) rat compared to a predominantly neutro-
philic response in Sprague–Dawley (SD) rats. The re-
sponse to AgNPs by direct inhalation into lungs, which
would be the main route of exposure if humans were ex-
posed to AgNPs from consumer products, remains un-
clear particularly in the potential differences in the
response between the 2 rat strains. The BN rat is known
to readily develop features of allergic asthma, namely
lung eosinophilia and bronchial hyperresponsiveness
(BHR) following sensitisation and exposure to allergens
and possess features of chronic lung inflammation in
contrast to the SD rat [17–20].
AgNPs from consumer products are more likely to be
inhaled, and the potential toxic effects of AgNPs will
certainly depend on the route on entry of these NPs.
Therefore, in order to characterise further the bioreac-
tivity of inhaled AgNPs in the lungs, we have studied the
effect of freshly-generated uncoated silver nanoparticles
produced by a spark discharge generator. We deter-
mined the threshold lung deposited dose on the lung
inflammatory response and cytokine levels. An import-
ant determining factor of the pulmonary response is the
interactions of these particles with the lung lining fluid
constituents that include dipalmitoylated phospholipid
(DPPC) and surfactant-specific proteins A, B, C and D,
which influence the aggregation, dissolution and uptake
of these nanoparticles by pulmonary macrophages and
alveolar cells and hence their cytotoxicity [21–23]. We
therefore measured the distribution of the silver particles
in the lungs, assayed silver levels, and related these to
the surfactant composition and lung function changes.
We determined whether there would be differences in
these parameters between the 2 rat strains.
Methods
Generation of silver nanoparticle aerosol and exposure
system
Aerosols of AgNPs were generated using a spark gener-
ator (DNP 4000, Palas, Karlsruhe, Germany) by the
homogeneous nucleation of vapour produced between
two electrodes (5 mm length and 1 mm diameter silver
wire; Premion™ 99.999 % purity, Alfa Aesar™, Heysham,
UK) in an inert argon atmosphere at a flow rate of
5 L min−1, as previously described [24]. The rate of pri-
mary particle production and final size was dependent
on the sparking frequency (90–300 Hz). The particles
were passed through a krypon-85 charge neutraliser
(Model 3077A, TSI Incorporated, Shoreview, MN, USA)
and were diluted with oxygen and nitrogen to give a
total aerosol flow-rate of 9 L min−1. This was led into a
custom-built nose-only exposure manifold consisting of
4 chambers as previously described [24]. Animals were
held in restraining tubes attached to the chamber ports,
thus each had an individual aerosol supply directed to
the nose area.
Characterisation and monitoring of AgNPs
Aerosol mass concentrations were determined gravimet-
rically using Pallflex® emfab™ filters (Pall Life Sciences,
Ann Arbor, MI, USA) with the aerosol drawn at 2 L min
−1 with continuous monitoring using a TEOM™ ambient
particulate monitor (Model 1400a, Thermo Scientific,
Franklin, MA, USA) [24]. The AgNP aerosol was imme-
diately diluted to prevent coagulation using a Palas®
ejector dilution system (Model VKL 100, Palas GmbH,
Karlsruhe, Germany). HEPA-filtered compressed air was
supplied to the diluter, drawing a sample flow rate of
0.12 L min−1 from the exposure chamber and giving a
dilution ratio of 150 ± 3 %. A condensation particle
counter (CPC model 3775, TSI Inc., Shoreview, MN,
USA) continuously monitored the concentration of par-
ticle numbers with aerosol particle size distribution de-
termined using a scanning mobility particle sizer (SMPS;
model 3936 N76, TSI Inc., Shoreview, MN, USA) and
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aerosol particle shape using high resolution transmission
electron microscopy (TEM) (JEOL 3000 F, JEOL Inc.,
Tokyo, Japan) [24]. Projected area equivalent diameters
were calculated for >1500 particles randomly selected
using the image analysis software Image J (http://ima-
gej.nih.gov/ij/).
Dose estimation
Estimates of the deposited dose, D (μg), in the lung and
alveolar regions were determined using the formula, D =
C × MV × T × DE × 10−6, where C (μ/m3) is the aerosol
mass concentration, MV (ml/min) the rat minute venti-
lation, T (min) the exposure duration, and DE the de-
position efficiency. The minute ventilation was derived
from measurements of tidal volume (TV) and breath-
ing frequency (f ) of 6 rats of similar weight to those
used in this study made using head-out plethysmo-
graph (EMMS, Bordon, UK) for the duration of nose-
only inhalation experiments similar to those described
here. The average MV, TV and f were 190 mL/min,
1.6 ml and 130 min−1 respectively. The deposition ef-
ficiencies for the lung and alveolar regions, of 31 and
21 %, respectively, were calculated using the multiple-
path particle dosimetry (MPPD) model (version 2.11,
Applied Research Associates, Inc.) [25] using the
aerosol CMD and GSD (Table 1) and the breathing
parameters indicated above.
Study design
The experiments were performed within the legal frame-
work of the United Kingdom under a Project License
granted by the Home Office of Her Majesty’s govern-
ment. The researchers hold Personal Licenses provided
by the Home Office to perform the experiments in the
rat species described here (Project Licence number: PPL
70/7581). These experiments were approved by the Im-
perial College BioSciences Animal Ethics Committee.
Male pathogen-free Sprague–Dawley (SD) (10–12
weeks, 250–320 g) and Brown-Norway (BN) rats (10–12
weeks, 260–380 g) were purchased from Harlan, UK and
housed under filter tops. Rats were randomly assigned
into groups and exposed for 3 h on one day (low dose)
or for 3 h on four consecutive days (high dose). Three
exposure conditions were defined: filtered air only con-
trols for 3 h on 4 consecutive days, low dose AgNP ex-
posure and high dose AgNP exposure (Table 1).
Following exposure, the rats were returned to their cages
for either 24 h or 7 days.
Respiratory mechanics
Respiratory mechanics was measured by the forced os-
cillation technique at pulmonary end- expiratory pres-
sures (PEEPs) of 3 cm H2O. Rats were anesthetised with
ketamine (80 mg/Kg) and Xylazine (10 mg/Kg) i.p. and
the depth of anaesthesia was quantified by loss of pedal
reflex and by pulse oximetry, using the MouseOx Plus
[STARR Life Sciences Corp., Oakmont, PA]. Rats were
ventilated through a tracheostomy (10 mL/Kg air at 90
breaths per minute) using a computer-controlled ventila-
tor (Spira, EMMS, UK). Three successive deep lung in-
flations (30 cmH20) were performed to standardise
volume history. Tdal breathing was interrupted by an 8 s
broadband input signal, containing multiple frequencies
between 0.5 and 20Hz. Respiratory impedance was cal-
culated at each frequency using the Fast Fourier trans-
formation of the pressure and flow signals. As a function
of frequency, the impedance (Zrs) data can be separated
into both resistance (RL) and elastance (EL) spectrawhich
were fitted to a constant phase model which partitions
the respiratory mechanics into the central airway (Rn)
and coefficients of tissue damping (G) and tissue elas-
tance (H) [26].
Bronchoalveolar lavage (BAL)
BAL was performed as previously described [15]. Dif-
ferential cell counts were performed on cytology of
BAL. BAL supernatants were stored for analysis of
various analytes.
Table 1 Characterisation of spark generated silver nanoparticles and lung burden on each of the exposure conditions for the two
rat strains
Sprague–Dawley rats Brown-Norway rats
Control Low dose High dose Control Low dose High dose
Count Median Diameter (nm) - 13.4 ± 1.0 14.1 ± 2.3 - 15.9 ± 0.8 15.7 ± 2.8
Geometric Standard Deviation - 1.60 ± 0.03 1.58 ± 0.06 - 1.58 ± 0.02 1.56 ± 0.06
Concentration /cm3 <1 (4.50 ± 0.21) x 107 (4.55 ± 0.70) x 107 <1 (3.89 ± 0.18) x 107 (3.68 ± 0.48) x 107
Mass concentration (μg/m3) - 801 ± 33 670 ± 49 - 791 ± 32 617 ± 25
Exposure duration (mins) 720 180 720 720 180 720
Lung burden (μg) 0 8 28 0 8 26
Alveolar dose (μg) 0 6 19 0 6 18
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Tissue processing and staining
Paraffin blocks were prepared from lungs and sections
stained with hematoxylin and eosin (H & E) and carbol-
chromotrope for visualisation of eosinophils as previ-
ously described [15]. The lung inflammatory response
was measured on a 0–3 scale, as previously defined [15].
Eosinophils in the lamina propria of largest airways in
each lung section were counted around 5 × 2nd-3rd
generation large airways of ~10 mm in length. Eosino-
phils up to 2 mm from each airway were counted and
expressed as eosinophils per millimetre of basement
membrane length.
We also used a Silver Enhancing Kit (Cat no: SE100,
Sigma-Aldrich, Saint Louis, USA) to visualise silver
nanoparticles using light microscope with positive cells
appearing black. Uptake into cells in walls of bronchi or
blood vessels, alveoli septa and alveolar space of the left
lung lobe were counted. Twenty fields covering the
whole left section were counted and data are expressed
as number of positive silver cells per field.
Measurement of silver in lungs
We used different inductively-coupled plasma mass
spectrometry (ICP-MS) methods for each rat species.
For the Sprague–Dawley rats, the concentration of silver
in lung lobes was quantified by 7700 ICPMS machine
(Agilent Technologies) following digestion of tissue sam-
ples. A standard reference material was analysed with
samples (National Research Council Canada (LUTS-1)
non-defatted lobster hepatopancreas) and the detection
limit for the analysis was 5 ng per sample. For the
Brown-Norway rats, we used 7900 ICPMS machine
(Agilent Technologies) on snap-frozen tissue. After
freeze drying, tissues were digested by microwave and
ICPMS performed in no-gas mode using mass 107 as
the quantifier and mass 71 as the internal standard. The
ICP-MS was calibrated using silver standards diluted
from a 1 ppm stock.
Measurement of malondialdehyde
BAL malondialdehyde (MDA) was measured using a
HPLC system with fluorescent detection (Waters, Mil-
ford, MA, USA) set at 532 nm for the excitation wave-
length and 553 nm for the emission wavelength. A
Nova-Pak C18 column (Waters, Milford, MA, USA) was
used with a mobile phase that was composed of 40
methanol and 60 % water containing 50 mM KH2PO4
(pH = 6.8). The detection limit, extraction recovery and
analytical precision were 1.8 nM, 75.9, and 2.2 %,
respectively.
Total phospholipid and surfactant proteins in BAL
BAL supernatant was separated into two fractions using
differential centrifugation. 1 mL of BAL from the first
wash was centrifuged at 18,000 rpm for 30 min at 4 °C
to obtain large and small aggregate fractions. The large
aggregate (LA) fraction (pellet) contains phospholipids,
tubular myelin, lamellar bodies, large vesicles, SP-A, B
and C. The supernatant contains the small aggregate
fraction (SA) consisting of small vesicles, SP-D and little
surface functional surfactant [27]. The LA was re-
suspended in 40 μL of physiological saline and 5 μL was
separated into organic and aqueous fractions by a
chloroform and methanol extraction. The lower layer
containing the organic fraction was dried under nitro-
gen. Total organic phosphorus was extracted using a
perchloric acid digestion (70 %) for one hour at 200 °C,
with potassium phosphate standards treated in the same
way as the samples and assayed using the method of
Bartlett [28]. Organic phospholipid was expressed as μg
of total organic phosphate in 5 μL LA, equivalent to 1/
5 mL of BAL. Protein concentrations in the LA and SA
were determined by the Bio-rad assay. SP-D was mea-
sured in whole BAL supernatants by ELISA [Cusabio
Biotech Co., Suffolk, UK] and SP-B inthe LA fraction by
ELISA [Cusabio Biotech Co., Newmarket, Suffolk, UK.
Cytokine and chemokine levels in BAL
Cytokines and chemokines including KC, CCL11
(eotaxin), Interferon (IFN)-γ, IL-1β, IL-4, IL-6, IL-13, IL-
17A, CCL2 (MCP-1) and CCL3 (MIP-1α) were mea-
sured in BAL supernatants using a Milliplex MAP rat
cytokine panel (Millipore Analayte Kit Finder, Millipore
Ltd, Watford, UK) according to the manufacturer’s
specifications.
Data analysis
Data analysis was performed using Prism 5 software.
Data were treated non-parametrically as data was gener-
ally not normally distributed when tested using the
Shapiro-Wilk normality test. A non-parametric ANOVA
(Kruskal-Wallis test) was performed at each time point
and comparison of the means of the multiple groups
was assessed by Dunn’s post-hoc test. P values <0.05
were considered significant.
Results
AgNP dose in the lungs
The AgNPs had an average count median diameter
(CMD) spanning between 13.4 ± 1.0 nm and 15.9 ±
0.8 nm on the different days of exposure with particle
number concentrations between 3.68 ± 0.48 × 107 and
4.55 ± 0.70 × 107/cm3 (Table 1; Fig. 1). Mass concentra-
tions measured gravimetrically ranged from 617 ± 25 to
801 ± 33 μg/m3. Figure 1 shows representative images of
separate Ag nanospheres collected during exposures, il-
lustrating their spherical form. In SD rats, low and high
lung doses were estimated using deposition fractions
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from the MPPD model as 8 and 28 μg respectively, while
in BN rats, these were 8 and 26 μg. The equivalent
values for alveolar deposition were 6 and 19 μg for the
SD rats and 6 and 18 μg for the BN rat.
Quantification and localisation of silver in lung tissue
Silver levels in the lungs of SD rats exposed to an esti-
mated deposited dose of 28 μg of AgNP particles were
9.97 ± 2.79 μg/g (wet weight) at 24 h. Assuming a typical
rat lung weight of 1 g this suggests significant clearance
within the first 24 h, and lower levels of 4.99 ± 2.21 μg/g
wet weight at day 7 (P < 0.05), indicate further clearance
had occurred from the lung by this time (Fig. 2 a). The
silver concentration in BN rat lung at 24 h was
74.46 μg/g dry weight). Typically lung dry weight is
~20 % of wet weight so this corresponds to around
15ug/g wet weight, which is higher by 50 % compared to
that found in the SD rats. For the BN rats, there was a
non-significant reduction measured at Day 7 (Fig. 2 b),
which suggests slower clearance from the BN rat lung.
In BN rats, there was a clear dose-dependent increase
in the number of silver-positive staining cells in the lung
at both 1 and 7 days post inhalation, this dose-
dependent trend was less clear for the SD rats, particu-
larly at 1 day where the number for both doses were
very similar (Fig. 2 c & d). The numbers of silver positive
stained cells were between 2 and 3 times higher for the
BN compared to the SD rats for the high dose exposure.
Fig. 1 Panel a: Density of particles as a function of the diameter of silver nanoparticles measured during each of the experimental conditions for each
rat strain. BN-LD: Brown Norway rats exposed to low dose; BN-HD: Brown Norway rats exposed to high dose; SD-LD: Sprague–Dawley rats exposed to
low dose; SD-HD: Sprague–Dawley rats exposed to high-dose. Panel b: Representative high resolution transmission electron microscopy (TEM) images
of aerosol particles delivered to the exposure manifold at 12,000X magnification (scale bar 200 nm) (Panel B a) and 800,000X magnification (scale bar
2 nm) (Panel B b)
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For both SD and BN rats numbers of stained cells at 1
and 7 days were similar, indicating no consistent time-
dependence.
Silver staining was not observed in non-exposed SD
and BN lungs (Fig. 3 a & d). There were black silver par-
ticles observed at 24 h post-AgNP inhalation. Silver
positivity at 24 h was as strong as at 7 days after AgNPs
inhalation in both rat strains. Silver-positive cells con-
sisted mainly of macrophages scattered in the alveolar
space and lung interstitium of SD lungs (Fig. 3 b & c).
Silver-positive macrophages were embedded within the
inflammatory cells which infiltrate the alveolar septa and
lamina propria of blood vessels and airway mucosa and
were deposited in granulomas of BN lungs (Fig. 3 e & f).
Silver particles were also observed on the luminal sur-
face and on surface epithelium and subepithelial con-
nective tissue of terminal bronchioles, scarcely at day 1
but more prominent at day 7 (Fig. 3).
Lung inflammatory changes
Following inhalation of silver, there was a mild inflam-
mation with a few inflammatory cell infiltrations in the
bronchial and vascular walls and alveolar septa in SD
rat lungs (Fig. 4b & d) compared to the control air-
exposed rats (Fig. 4a & c). Overall, tissue inflammation
scores were increased in lungs of SD rats at both day 1
and 7 and at both exposure doses with the scores
remaining unchanged during that period (Fig. 5a). In
BN rats, there was a high level of baseline inflammation
that remained unchanged after inhalation of AgNPs at
both levels of exposure and on both day 1 and day 7
(Fig. 5c). Areas of inflammation consisting of eosino-
phils, neutrophils, and mononuclear cells in BN rat
lungs could be seen (Fig. 3e & f ). Eosinophil counts in
the airway wall were increased in BN rats at day 1 after
the 28 μg exposure dose but not at day 7 (Fig. 5d).
There was no eosinophil increase in the SD lung tissue
(Fig. 5b).
BAL inflammatory cells
In SD and BN rats, total cell numbers increased at 1 day
post inhalation of the high 28 μg AgNP (P = 0.0002 & p
< 0.02, respectively), and in SD rats, this remained ele-
vated at day 7 (Fig. 6). Low doses of AgNP (8 μg) did
not elicit an increase in cells. The increase in total cells
was reflected in an increase in neutrophils (P = 0.0002)
in SD rats, while there was both an increase in neutro-
phils (P < 0.02) and eosinophils (P < 0.01) in BN rats.
Neutrophil numbers fell but remained elevated in SD
rats at day 7 (P = 0.009). There was also a small increase
in lymphocyte numbers at the high dose exposure in SD
rats (P < 0.03; data not shown).
a b
c d
Fig. 2 Panels a & b: Silver quantification using ICP-MS in lung tissue following inhalation of the high dose of freshly-generated silver nanoparticles.
In both rat strains, there was a reduction in lung silver content at Day 7 compared to Day 1, although this only reached statistical significance in
the Sprague–Dawley rats. The silver lung content was higher in Brown-Norway rats compared to Sprague–Dawley rats. Panels c & d: Counts of
macrophages staining positive for silver in the lung tissue of Sprague Dawley and Brown Norway rats exposed to silver nanoparticles at 1 and 7 days
post inhalation at each lung dose deposition. Data for individual rats are shown with the median for each group denoted as a horizontal bar. *P < 0.05,
**P < 0.01, ***P < 0.001 versus the air only control within each time-point
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a b c
d e f
Fig. 3 Silver-enhancing and hematoxylin-eosin-stained Sprague–Dawley (SD) and Brown-Norway (BN) rat lung sections at 24 h post-treatment. Panels
a & d: SD and BN air control shows an absence of signal; silver-stained positive cells are seen as black or black brown positivity (red arrows). In Panel b,
SD at lung dose of 8 μg; in Panel c, at lung dose of 28 μg AgNPs and in Panel e, BN at lung dose 8 μg and Panel f, 26 μg AgNPs. Positive silver-stained
cells are deposited in granuloma of BN lungs (arrow head pointing multi-nuclear giant cells). There are high levels of eosinophilic inflammation (black
arrows) in BN lungs (internal scale bar = 20 μm for all)
Fig. 4 Silver-enhancing and hematoxylin-eosin-stained terminal bronchioles of Sprague–Dawley rat lungs showing no signals in air control at
24 h and 7 days (Panels a & c). In Panel b, a few black silver particles are deposited on the surface of epithelial cells (arrow) at 24 h after 28 μg
AgNPs inhalation. In Panel d, more visible agglomerated black silver positivity were observed on the luminal surface and on surface epithelial cells
(arrows) and subepithelial connective tissue (arrow heads) at 7 days post-8 μg AgNPs inhalation (internal scale bar = 20 μm for all)
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BAL total protein, malonaldehyde (MDA), phospholipid and
surfactant proteins
Total BAL protein increased in the SD rats at 28 μg dose
only (P < 0.001) at day 1, and in the BN rats at both 8 μg
(P < 0.02) and 26 μg (P < 0.01). Total BAL protein levels
returned to baseline levels by 7 daysay in both rat strains
(Fig. 7 a & e). In the SD rats, MDA increased at 1 day after
inhalation of 8 (P < 0.03) and 28 μg (P < 0.01) of AgNP,
with levels returning to baseline by day 7. There was a
similar trend in the BN rats but the increases were not sig-
nificant (Fig. 7 b & f).
In the SD rat, SP-D levels in whole BAL did not
change at 1 day while at 7 days, there was a decrease
after the high dose. In the BN rat, SP-D levels in-
creased after the low dose but not after the high dose
at 1 day (Fig. 7 d & h). There was no change in SP-
D at the 26 μg dose at 7 days for the BN rats. Total
phospholipid levels in the large aggregate fraction of
BAL increased according to the dose of AgNPs ex-
posed for both rat strains at day 1. By 7 day,
phospholipid level remained elevated in the SD rat
after the 26 μg dose, while in the BN rat, levels had
returned to baseline (Fig. 7 c & g).
BAL cytokines/chemokines
Most of the changes in cytokine levels occurred at day 1.
In the SD rat, levels of IL-1β, KC, IL-17A, CCL2 (MCP-
1) and CCL3 (MIP-1α) increased at the 28 μg dose, with
increases also seen at 8 μg for IL1β, KC and CCL3
(Fig. 8). On the other hand, levels of IFNγ fell in a dose-
dependent manner. CCL2 and CCL3 remained elevated
at the high dose at day 7. In the BN rat, there were simi-
lar trends apart from an additional increase in IL-6 at
day 1 at both 8 and 26 μg doses. Levels of KC, CCL2
and CCL3 were generally higher in BN rat compared to
SD rat. There were no changes in levels of IL-4, IL-13
and CCL-11 (eotaxin) (data not shown).
Lung function
There were no changes in large airway resistance (Rn),
tissue damping (G) or tissue elastance (H) in the SD rats
at either time-point compared with the air control at a
physiological PEEP of 3 cm H2O, suggesting normal air-
way and parenchymal functioning of the SD lung (data
not shown). In BN rats, at PEEP 3, Rn increased at both
AgNP doses, although this was only statistically signifi-
cant for the 8 μg dose (Fig. 9 a). Increasing the PEEP
a c
b d
Fig. 5 Lung tissue inflammatory scores (Panels a & b) and eosinophil counts per mm length of airway wall (Panels c & d) in Sprague Dawley
and Brown Norway rats exposed to silver nanoparticles at 1 and 7 days post inhalation as a function of lung deposited doses of silver. Individual
data-points shown for 8–12 rats per group with horizontal bar showing mean. *P < 0.05, **P < 0.01, ***P < 0.001 versus the air only control (0)
within each time-point
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from 3 to 6 and 9 cm H2O resolved the increase in Rn
recorded at PEEP 3 (Fig. 9 b & c). On the other hand, a
small non-significant decrease in Rn at 7 days at PEEP 3
for the 8 μg dose, was not resolved by PEEP suggesting
some ongoing effects on lung function. There was also a
significant increase in H for BN rats at PEEP 3 at the
highest dose (Fig. 9 d), suggesting effects on mechanical
pulmonary function also originated in the parenchyma
and that the BN rats had stiffer lungs. Again, increasing





Fig. 6 Differential cell counts in bronchoalveolar lavage fluid after inhalation of silver nanoparticles at 1 and 7 days post-inhalation in Sprague
Dawley rats (Panels a-d) and in Brown Norway rats (Panels e-h) as a function of lung dose. Data shown as mean ± SD (n = 8–12 rats per group).
*P < 0.05, **P < 0.01, ***P < 0.001 versus the Air only control (0) within each time-point
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increases in H, suggesting that this may be due to a re-
cruitment phenomenon as before (Fig. 9 e & f). Similar
to the SD rats, there were no changes in G in the BN
rats suggesting that no parenchymal distortion had oc-
curred (data not shown).
Discussion
In this study, we report that inhalation of freshly-
generated silver nanoparticles of spherical shape of 15 nm
diameter induced an acute pulmonary neutrophilic in-





Fig. 7 Levels of total protein (Panels a & e), malonaldehyde (MDA; Panels b & f) and surfactant protein D (SP-D; Panels d & h) in bronchoalveolar
lavage fluid in Sprague Dawley and Brown Norway rats as a function of deposited lung dose of silver nanoparticles. Phospholipid levels (Panels
c & g) were measured in the large aggregate fraction. Data shown as mean ± SD (n = 8–12 rats per group). *P < 0.05, **P < 0.01, ***P < 0.001
versus the Air only control (0) within each time-point
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Fig. 8 Cytokine levels in bronchoalveolar lavage fluid in Sprague Dawley and Brown Norway rats as a function of deposited lung dose of silver
nanoparticles. Data shown as mean ± SD (n = 8–12 rats per group). *P < 0.05, **P < 0.01, ***P < 0.001 versus the air only control (0) within
each time-point
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pro-neutrophilic cytokines in SD and BN rats. However,
there were differences between the 2 strains in that the
BN rat also showed an eosinophilic inflammation and also
was the only strain to respond with a deterioration of lung
function. In addition, our study further delineates the dif-
ferential response of the lungs of these 2 rat strains to in-
halation of silver nanospheres in relation to the clearance
of silver from the lungs and the phospholipid and surfac-
tant production.
Silver tracing and clearance in the lungs
The number of cells, particularly macrophages, contain-
ing silver increased with dose exposure in both strains,
with the number of silver-positive cells in the BN rat 2
to 3-fold higher than in the SD rat at each time-point
for the high dose. The uptake of nanoparticles into
macrophages is likely to result in oxidative stress, the re-
lease of pro-inflammatorymediators and subsequent pul-
monary inflammation [15, 29, 30]. Concomitantly, we
found that the amount of silver in the lungs persisted to
the seventh day, despite a small reduction by that time,
but the levels found in the lungs of Brown-Norway rats
were approximately 50 % higher than in the lungs of
Sprague–Dawley rats after the high dose exposure. The
levels of silver measured in our Sprague–Dawley rats
were higher than those previously reported in Sprague–
Dawley or Fischer rats exposed to spark-generated un-
coated silver nanoparticles of a similar size, partly due to
the higher levels of exposure we delivered in our study
[2, 6, 7, 31, 32]. The calculation of silver levels from the
day 1 and day 7 measurements in the Sprague–Dawley




Fig. 9 Large airway resistance (Rn) (Panels a, b & c) and tissue elastance (h) (Panels d, e & f ) in Brown Norway rats exposed to silver
nanoparticles at PEEP 3, 6 and 9 cm H2O, at 1 and 7 days post inhalation as a function of lung deposited doses of silver. Data shown as mean ±
SD, n = 6 rats per group. *P < 0.05 and **P < 0.01 versus the air only control (0) within each time-point
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range to the clearance of 15 nm spark-produced AgNPs
inhaled by Fischer rats at a lower concentration of
179 μg/m3 (compared to ~700 μg/m3 for our study) for
a similar exposure pattern (6 h/day for 4 days) of 62 %
between 1 and 7 days post exposure [6]. Clearance of
such uncoated AgNPs have been reported to be much
faster, for example in the study of Takenaka et al. [2], it
was 62 % one day after exposure, increasing to 96 % on
day 7 (clearance between 1 day and 7 days was 89 %) in
Fischer rats. In a recent study of nebulised AgNPs of pri-
mary particle size 20 nm suspended in citrate buffer with
a high mass concentration of 7.2 mg/m3 delivered to
Sprague–Dawley rats for 6 h, a clearance of 34 % be-
tween day 1 and day 7 was reported [33]. The compari-
son between different studies is difficult because of
differences in amount of exposure, dose of nanoparticles,
method of generation of nanoparticle aerosols, particle
size and even animal gender, but most of these studies
would indicate that the silver persists for a period of at
least 7 days after inhalation. In the study of Anderson
et al. [33], one third of the initial silver inhaled persisted
even at 56 days, and this was associated with a greater
persistence of silver-positive macrophages at 21 and
56 days. In our study, the clearance between 1 day and
7 days for the Brown-Norway rat compared to the Spra-
gue–Dawley rat was lower at 33 %, and was associated
with a 2 to 3-fold higher number of silver-containing
lung macrophages compared to SD lungs. It is possible
that the pre-inflamed lung of the Brown-Norway rat
may retain more nanoparticles with a slower clearance
rate leading to higher levels of silver found in the lungs
when compared to the Sprague–Dawley rat.
Phospholipid and surfactant levels and influence on lung
function
In accord with previous reports of the inhalation of nano-
particles of titanium oxide, silica or cadmium oxide or ul-
trafine diesel exhaust particles in rats or mice [34–37], we
found that inhalation of AgNPs dose-dependently induced
an increase in the levels of phospholipids and total protein
in bronchoalveolar lavage fluid maximal at day 1 to a simi-
lar extent in both strains. Coating of the AgNPs with
phospholipid may have important implications on pul-
monary homeostasis by interfering with the biophysical
surfactant function such as decreased adsorption of pul-
monary surfactant at the air-liquid interface as has been
observed for gold nanoparticles [23]. On the other hand,
we found that the inhalation of AgNPs resulted in
diametrically-different effects on the measured levels of
SP-D in BAL fluid. While there was a decrease in SP-D
levels in Sprague–Dawley rats at day 7 following the high
dose exposure, there was an increase in SP-D levels in
BAL from Brown-Norway rats at the low dose exposure at
day 1, with a non-significant increase at the high dose at
day 7. Interestingly, the levels of SP-D at baseline in BAL
fluid was nearly 3-fold higher in Sprague–Dawley rats
compared to Brown-Norway rats. The reduction in SP-D
in Brown-Norway rats may be due to increased SP-D
turnover by alveolar macrophages, possibly as a result of
binding to AgNPs [22]. The acute increase in SP-D levels
in day 1 seen in Brown-Norway rat may represent an in-
creased production from alveolar Type II cells. Increased
amounts of SP-D may lead to increased aggregation of
nanoparticles [21], hence targeting them towards macro-
phage and lung clearance [38]. In a recent study, we have
also shown that incubating AgNPs with CurosurfR re-
duced the amount of IL-6 and IL-8 release from human
alveolar Type 1 cells exposed to these AgNPs [39].
Lung function changes only occurred in Brown-
Norway rats indicating a greater sensitivity of the air-
ways and lungs to the effect of inhaled AgNPs, similar to
the lung function responses observed with instillation of
AgNPs [15]. Resolution of the increase in lung resistance
recorded at low positive end-expiratory pressure (PEEP)
by increasing PEEP suggests that this increase was a re-
cruitment phenomenon which affected dynamic breath-
ing that may be related to surfactant dysfunction rather
than inherent forces in the lung which can occur follow-
ing lung injury [40].
Inhalation versus direct instillation
The results of inhalation of AgNPs in the present study
can be compared with our own work on the effect of
direct instillation of these nanoparticles into the lungs
[15]. In the previous study, we instilled AgNPs at 20 nm
diameter capped with citrate or polyvinylpyrrolidone
(PVP), the diameter nearest to the spark-generated parti-
cles at an intra-tracheal dose of 30 μg in both strains. In-
deed, the pattern of responses in these 2 strains in terms
of the inflammatory response and of lung function
changes were similar for both strains, albeit a lesser re-
sponse by the inhaled route when a maximal dose of
26–28 μg was deposited in the lungs. The highest in-
haled dose used at which we saw an effect was acquired
over a period of 12 h of inhalation, while for the instilla-
tion, a larger bolus dose was administered over seconds.
Thus, with the instilled dose of both citrate and pvp-
capped 20 nm silver nanoparticles, we saw a neutrophilic
response at day 1 in both strains but only eosinophilic
response significant at day 7 in Sprague–Dawley rats.
Similarly, there was an increase in protein concentration
and levels of MDA in bronchoalveolar lavage fluid, with
increased levels of KC at day 1 in both strains. Changes
in lung function were only seen in Brown-Norway rats
at day 1 also, but not in Sprague–Dawley rats, changes
that were similar as those observed in the current study.
The inflammatory data we have observed are simialr to
those reported from a study of Silva et al. [41] who
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reported that instillation of AgNPs into the lungs of rats
induced an inflammatory response at day 7 with reso-
lution by day 21, while at day 56, there was no inflamma-
tory response and no evidence of airway wall remodelling.
By contrast, Song et al. [10] reported that in Sprague–
Dawley rats exposed to spark-generated AgNP aerosol,
there was persistence of mild inflammation observed at
12 weeks. Longer term exposure studies are needed.
Conclusions
The pre-existing inflammatory state of the Brown-
Norway rat is likely to underlie the increased amount of
silver retained in the lungs with a reduced clearance rate
that may underlie the increased inflammatory response,
induction of SP-D and phospholipid and airway and par-
enchymal dysfunction observed in this rat strain but not
in Sprague–Dawley rats. Our findings would indicate
that inhalation of AgNPs in people with pre-existing in-
flammation in the lungs such as asthma patients or
those with chronic obstructive pulmonary disease would
lead to a greater degree of inflammation with heightened
consequences on lung function.
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